PCSK9 Inhibitors: the difficult combination of scientific evidence and regulatory limitations
- 1 February 2018
- editorial
- Vol. 19 (2), 77-80
- https://doi.org/10.1714/2868.28938
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agentsEuropean Heart Journal, 2016
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular EventsThe New England Journal of Medicine, 2015
- Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular EventsThe New England Journal of Medicine, 2015
- PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trialThe Lancet, 2014
- Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trialThe Lancet, 2014
- Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trialAmerican Heart Journal, 2014
- Plasma proprotein convertase subtilisin–kexin type 9 is predominantly related to intermediate density lipoproteinsClinical Biochemistry, 2014
- Healthy Lifestyle Through Young Adulthood and the Presence of Low Cardiovascular Disease Risk Profile in Middle AgeCirculation, 2012
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trialsThe Lancet, 2010
- The Forgotten Majority: Unfinished Business in Cardiovascular Risk ReductionJournal of the American College of Cardiology, 2005